Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Wedbush analyst Robert Driscoll reiterates Alpine Immune Sciences (NASDAQ:ALPN) with a Neutral and maintains $65 price target.
Alpine Immune Sciences (NASDAQ:ALPN) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate o...
Unlock Vertex Pharmaceuticals' pioneering treatments, from the groundbreaking Trikafta for cystic fibrosis to the promising...
TD Cowen analyst Boris Peaker downgrades Alpine Immune Sciences (NASDAQ:ALPN) from Buy to Hold.
Leerink Partners analyst Thomas Smith downgrades Alpine Immune Sciences (NASDAQ:ALPN) from Outperform to Market Perform and ...
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-media...
Investors can breathe a sigh of relief on Thursday as last month’s Producer Price Index (PPI) inflation turned out slightly low...
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter f...
